Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Breast cancer, female
Stage/Subtype:  stage IIIA breast cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 187 for your search:
Start Over
MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MM-302-02-02-03, NCI-2014-02093, NCT02213744
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane with or without Chemotherapy in Treating Patients with Invasive RxPONDER Breast Cancer
Status: Active
Phase: Phase III
Type: Health services research, Treatment
Age: 18 and over
Trial IDs: S1007, NCI-2011-02623, CDR0000692475, PS1007_A11PAMDREVW01, SWOG-S1007, NCT01272037
Testosterone in Treating Postmenopausal Patients with Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 and over
Trial IDs: A221102, NCI-2012-00719, CDR0000730083, CALGB-A221102, NCCTG-N10C7, NCT01573442
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CBKM120F2303, NCI-2013-00017, 2012-002571-34, NCT01633060
Hormone Therapy with or without Everolimus in Treating Patients with Breast Cancer
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1207, NCI-2012-01995, CDR0000738280, S1207/NSABP B-53, SWOG-S1207, NCT01674140
A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Health services research, Treatment
Age: 18 and over
Trial IDs: GBG78/BIG 1-13/NSABP-B-54-I, NCI-2014-02553, 2013-001040-62, NCT01864746
Standard or Comprehensive Radiation Therapy in Treating Patients with Early-Stage Breast Cancer Previously Treated with Chemotherapy and Surgery
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NSABP-B-51, NCI-2012-03198, NSABP-B-51/RTOG-1304, NSABP PROTOCOL B-51/RTOG PROTOCOL 1304, NCT01872975
Lymph Node Dissection and Radiation Therapy in Treating Patients with Breast Cancer Previously Treated with Chemotherapy and Surgery
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: A011202, NCI-2013-00875, NCT01901094
A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 673-301, NCI-2014-00659, U1111-1155-7579, NCT01945775
Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients with Stage II-III Breast Cancer Undergoing Surgery
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: A011106, NCI-2013-01340, NCT01953588
Olaparib in Treating Patients with Triple-Negative Non-metastatic Breast Cancer Who Have Completed Definitive Local Treatment and Chemotherapy
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Natural history/Epidemiology, Treatment
Age: 18 and over
Trial IDs: NSABP-B-55, NCI-2014-00644, B-55/BIG 6-13, BIG 6-13, D081CC00006, NSABP B-55/BIG 6-13, NCT02032823
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over, postmenopausal if female
Trial IDs: CBYL719C2301, NCI-2015-01171, 2015-000340-42, NCT02437318
Platinum Based Chemotherapy or Capecitabine in Treating Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: EA1131, NCI-2014-01820, NCT02445391
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel with or without Carboplatin in Treating Patients with Triple-Negative Breast Cancer
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NRG-BR003, NCI-2015-00128, NRG-BR1428, NCT02488967
RAnDomized Trial of SPI-2012 Versus Pegfilgrastim in the Management of Chemotherapy Induced Neutropenia in Breast CANCEr Patients Receiving Docetaxel and Cyclophosphamide
Status: Active
Phase: Phase III
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: SPI-GCF-301, NCI-2016-00155, NCT02643420
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CP-MGAH22-04, NCI-2016-00295, NCT02492711
Trastuzumab in Treating Leptomeningeal Metastases in Patients with HER2-Positive Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 10C03, NCI-2011-00110, STU00040150, STU00040150-MOD0003, NCT01325207
Eribulin Mesylate and Cyclophosphamide in Treating Patients With Solid Tumor Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 80
Trial IDs: 11996, NCI-2012-00436, NCT01554371
Triciribine Phosphate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients with Stage IIB-IV Breast Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Over 18
Trial IDs: 2011-269, NCI-2013-01311, 007884, 11-051, PTX-200, PTX-200-BC-1501.1, TCN-PM, NCT01697293
A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GO29642, NCI-2013-00898, 2014-004852-77, ARN-810-001, NCT01823835
Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLEE011X2106, NCI-2013-01630, NCT01857193
Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLEE011X2107, NCI-2014-00139, NCT01872260
A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CA209-032, NCI-2013-02337, 2013-002844-10, NCT01928394
Start Over